We are live on ! Find out more
NVS icon

Novartis

1,306 hedge funds and large institutions have $14.7B invested in Novartis in 2024 Q2 according to their latest regulatory filings, with 133 funds opening new positions, 426 increasing their positions, 488 reducing their positions, and 65 closing their positions.

New
Increased
Maintained
Reduced
Closed

105% more first-time investments, than exits

New positions opened: 133 | Existing positions closed: 65

88% more funds holding in top 10

Funds holding in top 10: 815 (+7)

8% more capital invested

Capital invested by funds: $13.6B → $14.7B (+$1.08B)

4% more funds holding

Funds holding: 1,2531,306 (+53)

0.12% less ownership

Funds ownership: 6.41%6.29% (-0.12%)

11% less call options, than puts

Call options by funds: $219M | Put options by funds: $246M

13% less repeat investments, than reductions

Existing positions increased: 426 | Existing positions reduced: 488

Holders
1,306
Holders Change
+53
Holders Change %
+4.23%
% of All Funds
18.86%
Holding in Top 10
15
Holding in Top 10 Change
+7
Holding in Top 10 Change %
+87.5%
% of All Funds
0.22%
New
133
Increased
426
Reduced
488
Closed
65
Calls
$219M
Puts
$246M
Net Calls
-$26.9M
Net Calls Change
-$21.8M
Name Holding Trade Value Shares
Change
Change in
Stake
PTP
926
Platform Technology Partners
New York
$286K +$269K +2,683 New
CBTWT
927
Community Bank & Trust (Waco, Texas)
Texas
$284K -$2.51K -25 -0.9%
ESB
928
Essex Savings Bank
Connecticut
$284K -$61.3K -611 -19%
SAG
929
SageView Advisory Group
California
$283K -$435K -4,334 -62%
AA
930
Addison Advisors
Vermont
$283K +$35.2K +351 +15%
EWM
931
Elmwood Wealth Management
California
$283K -$528K -5,265 -66%
RC
932
Roundview Capital
New Jersey
$283K -$3.61K -36 -1%
OWA
933
Opal Wealth Advisors
New York
$282K -$1.41K -14 -0.5%
MFG
934
Magnus Financial Group
New York
$282K +$2.51K +25 +1%
BMSSC
935
B. Metzler seel. Sohn & Co
Germany
$281K -$193K -1,927 -42%
CC
936
Chicago Capital
Illinois
$281K
KA
937
Klingman & Associates
New York
$279K -$9.03K -90 -3%
SAA
938
Southeast Asset Advisors
Georgia
$279K -$6.42K -64 -2%
ATPW
939
Ashton Thomas Private Wealth
Arizona
$278K -$19K -189 -7%
MWA
940
Meridian Wealth Advisors
Texas
$277K
CPRC
941
Consolidated Portfolio Review Corp
New York
$277K -$5.02K -50 -2%
NERM
942
New England Research & Management
Illinois
$276K -$10K -100 -4%
PWP
943
Private Wealth Partners
California
$276K
FFA
944
Founders Financial Alliance
North Carolina
$274K +$301 +3 +0.1%
ES
945
Eagle Strategies
New York
$274K +$258K +2,570 New
GWM
946
GSB Wealth Management
Connecticut
$273K +$502 +5 +0.2%
BP
947
BBR Partners
New York
$273K -$461K -4,593 -64%
AL
948
Aspiriant LLC
California
$272K -$59.4K -592 -19%
NCM
949
Northside Capital Management
Oregon
$271K
MIM
950
Merrion Investment Management
New Jersey
$270K

NVS Hedge Fund Activity: Q2 2024 in Review

1,306 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q2 2024, worth a combined $14.7B — up 7.9% from $13.6B a quarter earlier.

Buyers outnumbered sellers: 133 funds opened new NVS positions and 65 closed out — a net gain of 68 holders — while 426 added to existing stakes and 488 trimmed.

The largest buyer was Dimensional Fund Advisors, adding an estimated $139M. The largest seller was Mondrian Investment Partners, cutting an estimated $79.6M.

  • 1,306 institutional investors held Novartis (NVS) as of Q2 2024, up from 1,253 in Q1 2024.
  • Funds reported $14.7B of Novartis stock for Q2 2024, up 7.9% quarter-over-quarter.
  • 133 funds opened new Novartis positions in Q2 2024 and 65 closed out, a net change of +68 holders.
  • The largest Novartis buyer in Q2 2024 was Dimensional Fund Advisors, an estimated $139M added.
  • The largest Novartis seller in Q2 2024 was Mondrian Investment Partners, an estimated $79.6M sold.

Based on aggregated 13F filings for Q2 2024.